Related Experiment Video
Updated: Jul 14, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Technosphere insulin technology
Peter C Richardson1, Anders H Boss
1MannKind Corporation, Danbury, Connecticut, USA.
Diabetes Technology & Therapeutics
|July 10, 2007
Summary
Technosphere Insulin (TI) offers a novel inhaled approach to prandial glucose control, mimicking natural insulin release. This new insulin formulation shows rapid absorption and a short duration of action, potentially improving diabetes management.
Area of Science:
- Pharmacology and Therapeutics
- Endocrinology and Metabolism
Background:
- Achieving an ideal prandial insulin response that mimics healthy individuals is a significant challenge in diabetes management.
- Injected insulins often struggle to replicate the rapid absorption and favorable duration of action characteristic of natural early-phase insulin release, which is impaired in diabetes.
Purpose of the Study:
- To evaluate Technosphere Insulin (TI), a novel inhaled formulation of regular human insulin, as a potential prandial insulin therapy.
- To assess the pharmacokinetic and pharmacodynamic profile of TI, focusing on its rapid absorption and onset of action.
Main Methods:
- Technosphere Insulin (TI) utilizes the Technosphere inhalation powder platform for pulmonary delivery of regular human insulin.
- Evaluation of TI's absorption, time to maximum effect, peak metabolic effect, and duration of glucose-lowering activity.
Main Results:
- TI demonstrates rapid absorption with a time to maximum effect of approximately 15 minutes.
- The metabolic effect of TI peaks around 1 hour post-administration, significantly earlier than other reported insulins.
- The majority of TI's glucose-lowering effect occurs within the first 3 hours, with preliminary studies indicating good tolerability.
Conclusions:
- Technosphere Insulin (TI) presents a promising novel inhaled option for prandial insulin therapy, designed to overcome limitations of injected insulins.
- Its rapid absorption and early peak action profile align with the goal of mimicking physiological insulin response.
- Ongoing Phase 3 studies are crucial for confirming the long-term efficacy and safety of TI in patients with type 1 and type 2 diabetes.
Related Concept Videos
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:05Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...